Loading...
•
Jun 30, 2023
Curis Q2 2023 Earnings Report
Curis reported second quarter 2023 financial results and business update.
Key Takeaways
Curis reported a net loss of $12.0 million, or $0.12 per share, for the second quarter of 2023. The company's cash, cash equivalents, and investments totaled $77.4 million, expected to fund operations into 2025. The partial clinical hold on the TakeAim Leukemia study was removed, and the RP2D for emavusertib monotherapy was confirmed at 300 mg BID.
Partial clinical hold on TakeAim Leukemia study removed.
Enrolling patients at confirmed RP2D in the TakeAim Leukemia Study.
Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib.
Strong balance sheet with $77.4 million in cash and investments; cash runway into 2025.
Forward Guidance
Curis expects its existing cash, cash equivalents and investments should enable it to maintain its planned operations into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...